Sera Prognostics was founded to develop diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. Sera’s tests are designed to give women and their physicians the power and time to make a difference in maternal and newborn health with individualized treatment and care plans.
The company has completed enrollment and is in the validation phase for the landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study. PAPR is an all-comer study representative of pregnant women in the U.S. It is the largest study of its kind and includes 5,501 women.
The company’s proteomic predictor of premature birth risk—the PreTRM® Test for Risk Management-became commercially available in the U.S. in early 2016.
VISION: EARLY PREDICTION OF PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS
To be a global leader in high-value women’s health diagnostics, delivering pivotal information to patients and physicians that will improve the health of pregnant women and newborns and simultaneously improve the economics of healthcare.